全文获取类型
收费全文 | 30325篇 |
免费 | 2043篇 |
国内免费 | 1113篇 |
专业分类
耳鼻咽喉 | 79篇 |
儿科学 | 540篇 |
妇产科学 | 311篇 |
基础医学 | 6655篇 |
口腔科学 | 382篇 |
临床医学 | 2903篇 |
内科学 | 5015篇 |
皮肤病学 | 751篇 |
神经病学 | 1442篇 |
特种医学 | 613篇 |
外国民族医学 | 4篇 |
外科学 | 1880篇 |
综合类 | 4391篇 |
现状与发展 | 5篇 |
一般理论 | 1篇 |
预防医学 | 2443篇 |
眼科学 | 312篇 |
药学 | 3119篇 |
10篇 | |
中国医学 | 766篇 |
肿瘤学 | 1859篇 |
出版年
2024年 | 37篇 |
2023年 | 383篇 |
2022年 | 580篇 |
2021年 | 1046篇 |
2020年 | 858篇 |
2019年 | 854篇 |
2018年 | 819篇 |
2017年 | 851篇 |
2016年 | 900篇 |
2015年 | 915篇 |
2014年 | 1398篇 |
2013年 | 2085篇 |
2012年 | 1387篇 |
2011年 | 1539篇 |
2010年 | 1200篇 |
2009年 | 1210篇 |
2008年 | 1176篇 |
2007年 | 1288篇 |
2006年 | 1106篇 |
2005年 | 1088篇 |
2004年 | 1010篇 |
2003年 | 965篇 |
2002年 | 799篇 |
2001年 | 771篇 |
2000年 | 728篇 |
1999年 | 609篇 |
1998年 | 613篇 |
1997年 | 631篇 |
1996年 | 579篇 |
1995年 | 664篇 |
1994年 | 650篇 |
1993年 | 546篇 |
1992年 | 557篇 |
1991年 | 539篇 |
1990年 | 478篇 |
1989年 | 352篇 |
1988年 | 354篇 |
1987年 | 294篇 |
1986年 | 237篇 |
1985年 | 437篇 |
1984年 | 318篇 |
1983年 | 193篇 |
1982年 | 155篇 |
1981年 | 87篇 |
1980年 | 50篇 |
1979年 | 39篇 |
1978年 | 40篇 |
1977年 | 16篇 |
1976年 | 15篇 |
1972年 | 8篇 |
排序方式: 共有10000条查询结果,搜索用时 541 毫秒
991.
《Expert opinion on biological therapy》2013,13(11):1175-1192
A growing understanding of the molecular mechanisms involved in cancer biology and continuous refinement of available technologies for drug discovery have prompted the development of new therapeutic tools targeting specific cancer-associated molecular pathways. Among these so-called biological therapies, monoclonal antibodies have now reached the time of clinical application. Besides initial development of the murine antibody edrecolomab, the impact of monoclonal antibodies on cancer therapy has recently been clearly demonstrated in colorectal cancer by targeting two major pathways critical to tumourigenesis: the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) signalling pathways. These antibodies showed significant clinical activity in advanced colorectal cancer, especially when combined with chemotherapy. This paper reviews the status of the monoclonal chimeric antibody cetuximab (Erbitux®) and other anti-EGFR antibodies, and of bevacizumab (Avastin®; an anti-VEGF humanised monoclonal antibody), in colorectal cancer treatment. 相似文献
992.
There is a need for developing improved therapeutic options for the management of prostate cancer, able to inhibit proliferation of precancerous and malignant lesions and/or to improve the effectiveness of conventional chemopreventive and chemotherapeutic agents. In this perspective, application of nanotechnology based strategies for the delivery of natural compounds for effective management of the disease is being actively researched. Here, after highlighting the most promising natural compounds for chemoprevention and chemotherapy of prostate cancer, the state of the art nanotherapeutics and the recent proof-of-concept of “nanochemoprevention”, as well as the clinical development of promising targeted nanoprototypes for use in the prostate cancer treatment are being discussed. 相似文献
993.
《Journal of microencapsulation》2013,30(2):105-114
An eluting-stent system with mAb dispersed in the PLLA (poly (L-lactic acid)) was validated in vitro. Specifically designed spray equipment based on the principle of ultrasonic atomization was used to produce a thin continuous PLLA (poly (L-lactic acid)) polymer coating incorporating monoclonal antibody (mAb). This PLLA coating was observed in light microscopy (LM) and scanning electron microscopy (SEM). The concentration of the monoclonal antibody (mAb) to the platelet glycoprotein (GP) IIIa receptor and the eluting rate were then measured by a radioisotope technique with 125I-labelled GP IIIa mAb. An in vitro perfusion circuit was designed to evaluate the release rates at different velocities (10 or 20 ml min?1). The PLLA coating was thin and transparent, uniformly distributed on the surface of the stent. Three factors influenced its thickness: PLLA concentration, duration and gas pressure. The concentration of mAb was influenced by the duration of absorption and the concentration of the mAb solution; the maximum was 1662.23 ± 38.83 ng. The eluting rate was fast for the first 2 h, then decreased slowly and attained 80% after 2 weeks. This ultrasonic atomization spray equipment and technological process to prepare protein eluting-stents were proved to be effective and reliable. 相似文献
994.
《Autoimmunity》2013,46(4):219-224
Collagen induced arthritis (CIA) is an animal model of inflammatory polyarthritis. Type II collagen is the major matrix protein of hyaline cartilage. Susceptibility to CIA is linked to the Major Histocompatibility Complex Class II genes but the presence of T cells expressing specific variable beta (Vβ) chain of their T cell receptor (TCR) is also required. Pretreatment with the monoclonal antibody H57-597 directed against the TCR αβ framework prevented the onset of arthritis in the majority of animals. The depletion of the T cell population did not lead to any apparent health problems. These experiments demonstrate the important role of the αβ T cell and its receptors in the CIA model. Further, anti-TCR αβ antibodies may be of value in the therapy of autoreactive disorders. 相似文献
995.
《Journal of thoracic oncology》2017,12(9):1413-1420
IntroductionMultimodality therapy has curative potential in locally advanced NSCLC. Mediastinal nodal sterilization (MNS) after induction chemoradiotherapy (CRT) can serve as an intermediate marker for efficacy. NRG Oncology Radiation Therapy Oncology Group (RTOG) 0229 demonstrated the feasibility and efficacy of combining full-dose radiation (61.2 Gy) with chemotherapy followed by resection and chemotherapy. On the basis of that experience and evidence that EGFR antibodies are radiosensitizing, we explored adding panitumumab to CRT followed by resection and consolidation chemotherapy in locally advanced NSCLC with a primary end point of MNS.MethodsPatients with resectable locally advanced NSCLC were eligible if deemed suitable for trimodality therapy before treatment. Surgeons were required to demonstrate expertise after CRT and adhere to specific management guidelines. Concurrent CRT consisted of weekly carboplatin (area under the curve = 2.0), paclitaxel (50 mg/m2), and 60 Gy of radiation therapy delivered in 30 fractions. There was a 2:1 randomization in favor of panitumumab at 2.5 mg/kg weekly for 6 weeks. The mediastinum was pathologically reassessed before or at the time of resection. Consolidation chemotherapy was weekly carboplatin (area under the curve = 6) and paclitaxel, 200 mg/m2 every 21 days for two courses. The study was designed to detect an improvement in MNS from 52% to 72%. With use of a 0.15 one-sided type 1 error and 80% power, 97 patients were needed.ResultsThe study was opened in November 2010 and closed in August 2015 by the Data Monitoring Committee after 71 patients had been accrued for futility and excessive toxicity in the experimental arm. A total of 60 patients were eligible: 19 patients (86%) who received CRT and 29 (76%) who received CRT plus panitumumab and underwent an operation. With regard to postoperative toxicity, there were three grade 4 adverse events (13.6%) and no grade 5 adverse events (0%) among those who received CRT versus six grade 4 (15.8%) and four grade 5 adverse events (10.5%) among those who received CRT plus panitumumab. The MNS rates were 68.2% (95% confidence interval: 45.1–86.1) and 50.0% (95% confidence interval: 33.4–66.6) for CRT and CRT plus panitumumab, respectively (p = 0.95).ConclusionThe addition of panitumumab to CRT did not improve MNS. There was an unexpectedly high mortality rate in the panitumumab arm, although the relationship to panitumumab is unclear. The control arm had outcomes similar to those in NRG Oncology RTOG 0229. 相似文献
996.
997.
Eunyoung Lee Susun An Moon‐sup Im Han Kon Kim Tae Ryong Lee 《Skin research and technology》2011,17(3):320-325
Background: The aim of this study was to develop a method for the evaluation of subtle change in skin roughness caused by cleansing products under mild application conditions using a non‐invasive three‐dimensional (3D) analysis system. Methods: A double‐blind comparative study of the modified soap chamber test was performed using two soap bars and a syndet bar. Skin changes were evaluated by visual scoring [mean cumulative irritation index (MCII)] and by bioengineering measurements [transepidermal water loss (TEWL), skin capacitance, and skin surface roughness]. Results: MCII of the syndet bar was statistically higher than that of one soap bar, and TEWL increase after application of the syndet bar was statistically higher than that of both soap bars. Skin capacitance decreased significantly only after application of the syndet bar. The change in the average roughness of the skin surface was significantly greater after the application of the syndet bar than with classic soap bars. Conclusion: A simple, fast, and objective evaluation of skin surface topography was performed using a modified soap chamber test and a non‐invasive 3D analysis system. The results suggest that measurement of skin roughness using a non‐invasive 3D analysis system might be a good method for the evaluation of a subtle change caused by cleansing products under mild application conditions. 相似文献
998.
S. Mat W. Borsini S. Ambrosini L. Toscani A. Barilaro S. Piacentini S. Sorbi F. Lolli 《European journal of neurology》2011,18(8):1067-1073
Background and purpose: Antibodies directed against myelin‐associated glycoprotein (MAG) are believed to be the most frequent biologic marker of the neuropathies associated with IgM monoclonal gammopathy of undetermined significance (MGUS). The objective of this study was to examine the prevalence of antiganglioside and/or sulfatide‐positive patients and their clinical findings, including therapeutic response, compared to anti‐MAG‐positive or seronegative patients. Methods: We prospectively followed 46 patients with MGUS who were diagnosed in our tertiary referral centers for polyneuropathy since 1997. All patients underwent nerve conduction studies and were tested for anti‐MAG, gangliosides, and sulfatide antibodies. All the anagraphic and clinical data (including symptoms, disability scale, therapy, secondary malignancy development) were recorded in a database and compared between three patients’ groups (anti‐MAG‐positive; antiganglioside/sulfatide‐positive; no reactivity). Results: Anti‐MAG reactivity was present in 17 (37%) patients; other 17 patients (37%) had antiganglioside/sulfatide reactivity and 12 (26%) had no reactivity. Patients with antiganglioside/sulfatide positivity, although heterogeneous by a clinical and neurophysiological point of view, had the most severe neuropathic manifestations and a higher disability score at nadir (P < 0.001). These patients had a better response to both intravenous immunoglobulin therapy and rituximab. Conclusions: Our results suggest that antiganglioside/sulfatide‐positive patients form a relevant portion of patients with MGUS‐associated polyneuropathy seen in tertiary care centers and should be considered in future studies on treatment response. 相似文献
999.
Eiji MUROI Fumihide OGAWA Toshifumi YAMAOKA Fumiko SUEYOSHI Shinichi SATO 《The Journal of dermatology》2010,37(1):81-84
We report a 4-year-old girl presenting with progressive linear scleroderma affecting the right leg. Biopsy specimen disclosed typical histopathological findings of localized scleroderma. Right leg magnetic resonance imaging (MRI) showed high signal areas on T2 -weighted images on the subcutaneous fatty tissue, muscles and bone marrow, suggesting that skin inflammation extended to the bone marrow. Oral corticosteroid therapy was instituted with improvement of both skin sclerosis and MRI findings. Our observations suggest that MRI examination should be considered in patients with localized scleroderma to evaluate the extension of the inflammation. 相似文献
1000.
《Journal of the American College of Cardiology》2020,75(22):2851-2862
Technetium-labeled cardiac scintigraphy (i.e., Tc-PYP scan) has been repurposed for the diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM). Validated in cohorts of patients with heart failure and echocardiographic and/or cardiac magnetic resonance imaging findings suggestive of cardiac amyloidosis, cardiac scintigraphy can confirm the diagnosis of ATTR-CM only when combined with blood and urine testing to exclude a monoclonal protein. Multisocietal guidelines support the nonbiopsy diagnosis of ATTR-CM using cardiac scintigraphy, yet emphasize its use in the appropriate clinical context and the crucial need to rule out light chain amyloid cardiomyopathy. Although increased awareness of ATTR-CM and the advent of effective therapy have led to rapid adoption of diagnostic scintigraphy, there is heterogeneity in adherence to consensus guidelines. This perspective outlines clinical scenarios wherein findings on technetium-labeled cardiac scintigraphy have been misinterpreted, reviews causes of false-negative and false-positive results, and provides strategies to avoid costly and potentially fatal misdiagnoses. 相似文献